-
Loading metrics
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study
- Jesús Troya,
- Pablo Ryan,
- Esteban Ribera,
- Daniel Podzamczer,
- Victor Hontañón,
- Jose Alberto Terrón,
- Vicente Boix,
- Santiago Moreno,
- Pilar Barrufet,
- Manuel Castaño
x
- Published: October 11, 2016
- https://doi.org/10.1371/journal.pone.0164455